Dmitry Balyasny’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.84M | Sell |
9,927
-255,733
| -96% | -$94.8M | ﹤0.01% | 1496 |
|
|
2026
Q1 | $77.8M | Buy |
265,660
+247,292
| +1,346% | +$81.3M | 0.1% | 221 |
|
|
2025
Q4 | $6.44M | Buy |
18,368
+9,665
| +111% | +$3.27M | 0.01% | 1266 |
|
|
2025
Q3 | $2.81M | Sell |
8,703
-16,103
| -65% | -$5.01M | ﹤0.01% | 1647 |
|
|
2025
Q2 | $9.65M | Buy |
24,806
+3,569
| +17% | +$1.44M | 0.01% | 982 |
|
|
2025
Q1 | $9.24M | Buy |
21,237
+726
| +4% | +$291K | 0.02% | 955 |
|
|
2024
Q4 | $7.57M | Sell |
20,511
-115,037
| -85% | -$48.1M | 0.01% | 1093 |
|
|
2024
Q3 | $70.5M | Sell |
135,548
-29,856
| -18% | -$15.9M | 0.12% | 206 |
|
|
2024
Q2 | $89.6M | Buy |
165,404
+164,604
| +20,576% | +$87M | 0.16% | 148 |
|
|
2024
Q1 | $415K | Sell |
800
-3,001
| -79% | -$1.49M | ﹤0.01% | 2123 |
|
|
2023
Q4 | $1.79M | Sell |
3,801
-87
| -2% | -$40.2K | ﹤0.01% | 1490 |
|
|
2023
Q3 | $1.69M | Sell |
3,888
-189
| -5% | -$85.7K | ﹤0.01% | 1417 |
|
|
2023
Q2 | $1.81M | Buy |
+4,077
| New | +$1.88M | ﹤0.01% | 1411 |
|
|
2023
Q1 | – | Sell |
-72,982
| Closed | -$37.4M | – | 2786 |
|
|
2022
Q4 | $37.4M | Buy |
+72,982
| New | +$37.1M | 0.1% | 251 |
|
|
2022
Q3 | – | Sell |
-47,588
| Closed | -$23M | – | 2937 |
|
|
2022
Q2 | $23M | Buy |
+47,588
| New | +$23.5M | 0.07% | 376 |
|
|
2021
Q4 | – | Sell |
-6,844
| Closed | -$2.55M | – | 2328 |
|
|
2021
Q3 | $2.55M | Sell |
6,844
-18,034
| -72% | -$6.85M | 0.01% | 1049 |
|
|
2021
Q2 | $9.5M | Buy |
+24,878
| New | +$9.51M | 0.05% | 535 |
|
|
2021
Q1 | – | Sell |
-40,489
| Closed | -$13M | – | 1842 |
|
|
2020
Q4 | $13M | Buy |
+40,489
| New | +$12.4M | 0.07% | 366 |
|
|
2020
Q2 | – | Sell |
-94,895
| Closed | -$21.5M | – | 1217 |
|
|
2020
Q1 | $21.5M | Buy |
+94,895
| New | +$25.9M | 0.26% | 106 |
|
|
2019
Q3 | – | Sell |
-2,804
| Closed | -$791K | – | 1277 |
|
|
2019
Q2 | $791K | Sell |
2,804
-1,262
| -31% | -$345K | 0.01% | 1137 |
|
|
2019
Q1 | $1.17M | Sell |
4,066
-42,928
| -91% | -$12.4M | 0.01% | 973 |
|
|
2018
Q4 | $12.3M | Buy |
46,994
+34,712
| +283% | +$9.54M | 0.09% | 305 |
|
|
2018
Q3 | $3.37M | Sell |
12,282
-7,063
| -37% | -$1.83M | 0.02% | 828 |
|
|
2018
Q2 | $4.61M | Sell |
19,345
-3,341
| -15% | -$774K | 0.02% | 689 |
|
|
2018
Q1 | $4.98M | Buy |
22,686
+19,486
| +609% | +$4.58M | 0.02% | 711 |
|
|
2017
Q4 | $720K | Sell |
3,200
-25,367
| -89% | -$5.4M | ﹤0.01% | 1429 |
|
|
2017
Q3 | $5.42M | Sell |
28,567
-29,904
| -51% | -$5.69M | 0.02% | 688 |
|
|
2017
Q2 | $11M | Buy |
58,471
+49,350
| +541% | +$8.87M | 0.05% | 512 |
|
|
2017
Q1 | $1.51M | Sell |
9,121
-29,410
| -76% | -$4.68M | 0.01% | 990 |
|
|
2016
Q4 | $5.54M | Buy |
+38,531
| New | +$5.16M | 0.03% | 664 |
|
|
2016
Q2 | – | Sell |
-4,941
| Closed | -$687K | – | 1230 |
|
|
2016
Q1 | $687K | Sell |
4,941
-496
| -9% | -$66.3K | ﹤0.01% | 820 |
|
|
2015
Q4 | $758K | Buy |
+5,437
| New | +$749K | 0.01% | 751 |
|
Other funds holding ELV
Dmitry Balyasny's ELV Position: Q2 2026 in Review
Dmitry Balyasny reduced its Elevance Health (ELV) stake by 96% in Q2 2026, selling an estimated $94.8M and leaving 9,927 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1496.
Dmitry Balyasny first reported a position in ELV in Q4 2015 and has held it in 32 quarters since. The position peaked at $89.6M in Q2 2024. 1,596 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Dmitry Balyasny held 9,927 shares of Elevance Health worth $3.84M as of Q2 2026.
- Dmitry Balyasny sold 255,733 Elevance Health shares in Q2 2026, an estimated $94.8M.
- Elevance Health made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1496 holding.
- Dmitry Balyasny first reported a position in Elevance Health in Q4 2015 and has held it in 32 quarters since.
- Dmitry Balyasny's Elevance Health position peaked at $89.6M in Q2 2024.
- 1,596 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.